Cervical cancer and cervical precancerous lesions
Conditions
Interventions
Sponsors
The First Affiliated Hospital of Xiamen University
Eligibility
Sex/Gender
Female
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Clear cervical screening and diagnosis: at least one previous cervical cytology or histological biopsy, obtain clear diagnostic results (normal, CIN or cervical cancer, etc.) , pathological diagnosis as the gold standard group. 2.Have been tested for PAX1 and JAM3 methylation: subjects have been tested for PAX1 and JAM3 methylation levels in cervical exfoliated cells (usually as a shunt test after HPV positivity) during the diagnostic process, and have a test report to check. 3.Complete clinical data: complete clinical medical records, including basic demographic data (age, marital history, etc.) , HPV infection test results, cytological results, pathological diagnosis, treatment process, etc. . 4.Sample availability: the amount of corresponding cervical cell preservation solution or tissue samples retained in the Biobank is sufficient and the quality meets the requirements of follow-up experiments (such as non-obvious degradation of contamination) .
Exclusion criteria
Exclusion criteria: 1.Comorbid other site malignancies: patients with a previous or current diagnosis of a malignancy other than cervical cancer were not included in this study to avoid the impact of other tumor-related treatments on the index. 2.Serious complications or infections: such as severe pelvic inflammatory disease, immunodeficiency, AIDS and other conditions that may affect the vaginal flora or immune status should be excluded. 3.Pregnant women: the hormone level and immune status of pregnant women are special, which may affect the related indicators and are not representative, so they are not included. 4.Incomplete data or substandard samples: those with missing key clinical information or improperly preserved samples that prevent scheduled testing should be excluded. 5.Recent use of antibiotics: history of antibiotic therapy within 3 months before sampling.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vaginal microbiome;HPV infection;DNA breakome of the vaginal epithelium;Point Mutation of gene;The genome of the vaginal epithelium;Severity of Cervical Lesions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Host genomic variations (mutations, CNVs, TMB);DNA damage markers (?-H2AX, Comet assay, 8-oxo-dG);Combined PAX1/JAM3 positivity; | — |
Countries
China
Contacts
Public ContactLian Jiabian
The First Affiliated Hospital of Xiamen University
Outcome results
None listed